Targeted & controlled bone healing

KUR-113 consists of a natural fibrin-based healing matrix with an immobilized targeted bone growth factor (PTH). KUR-113 is designed to be applied directly into and around an inter-body spinal cage as a gel, where it polymerizes in situ.

This is in contrast to most products on the market which are solids, granules or sponges. Studies show that the combination of the natural healing matrix with the localized bone growth factor induces a response from the adjacent vertebrae, facilitating fusion through the cage.

The program has completed non-clinical testing and is currently being prepared for a Phase II/III program.  It is anticipated that this program will be carried out in the US and the first patient will be treated in 2019.

Kuros Biosciences AG
Wagistrasse 25, 8952 Schlieren, Switzerland
Tel: +41 44 733 47 47   Fax: +41 44 733 47 40   Email: info@kurosbio.com

About Kuros

  1. Overview
  2. Executive Committee
  3. Board
  4. Careers

Products

  1. MagnetOs

Pipeline

  1. Pipeline
  2. Spinal fusion
    KUR-113
  3. Fracture repair
    KUR-111
    KUR-113
  4. Surgical Sealants
    Neuroseal (KUR-023)

Technologies

  1. Surface Science Technology
  2. Fibrin-Based
  3. Synthetic Cross-Linking Technology
  4. Immune Modulation

Partnerships

  1. Collaborations
  2. Business Development

Investors

  1. Share price
  2. Regulatory filings
  3. Reports & Presentations
  4. Calendar
  5. Corporate governance
  6. Stay informed

News

  1. Press releases
  2. Conferences & Events

Contact

  1. Location
KUR-113

KUR-113 consists of a natural fibrin-based healing matrix with an immobilized targeted bone growth factor (PTH). KUR-113 is designed to be applied directly into and around an inter-body spinal cage as a gel, where it polymerizes in situ.

This is in contrast to most products on the market which are solids, granules or sponges. Studies show that the combination of the natural healing matrix with the localized bone growth factor induces a response from the adjacent vertebrae, facilitating fusion through the cage.

The program has completed non-clinical testing and is currently being prepared for a Phase II/III program.  It is anticipated that this program will be carried out in the US and the first patient will be treated in 2019.